Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children

Leukemia

Volumn 27, Issue 12, 2013, Pages 2413-2416

  Tomizawa, D ^a   Tawa, A ^b   Watanabe, T ^c   Saito, A M ^d   Kudo, K ^e   Taga, T ^f   Iwamoto, S ^g   Shimada, A ^h   Terui, K ⁱ   Moritake, H ^j   Kinoshita, A ^k   Takahashi, H ^l   Nakayama, H ^m   Koh, K ⁿ   Kigasawa, H ^o   Kosaka, Y ^p   Miyachi, H ^q   Horibe, K ^d   Nakahata, T ^r   Adachi, S ^s  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^g MIE UNIVERSITY   (Japan)

^h OKAYAMA UNIVERSITY   (Japan)

ⁱ HIROSAKI UNIVERSITY   (Japan)

^j UNIVERSITY OF MIYAZAKI   (Japan)

^k ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l Saiseikai Yokohama City Southern Hospital   (Japan)

^m FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

ⁿ SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^o KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^p Hyogo Children's Hospital   (Japan)

^q TOKAI UNIVERSITY   (Japan)

^r KYOTO UNIVERSITY   (Japan)

^s KYOTO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD135 ANTIGEN; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILDHOOD LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION;

ADOLESCENT; ANTHRACYCLINES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; RECURRENCE;

EID: 84890426406     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.153     Document Type: Letter

References (13)

1. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-552.
2. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M et al. Riskstratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009; 27: 4007-4013.
3. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011; 118: 5409-5415.
4. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896-903.
5. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer research 1998; 58: 4173-4179.
6. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl JMed 2009; 361: 1235-1248.
7. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl JMed 2009; 361: 1249-1259.
8. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13: 819-829.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
10. Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130-2138.
11. Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006; 107: 1806-1809.
12. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 Trial. J Clin Oncol 2011; 29: 369-377.
13. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508-1516.